Key Details
Price
$11.13PE Ratio
278.13Annual ROE
6.66%Beta
0.73Events Calendar
Next earnings date:
Mar 12, 2025Recent quarterly earnings:
Nov 4, 2024Recent annual earnings:
Mar 12, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
NEW YORK CITY, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
NEW YORK CITY, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
LOS ANGELES, CA / ACCESS Newswire / January 29, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Enfusion board breached its fiduciary duties to shareholders.
NEW YORK CITY, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
LOS ANGELES, CA / ACCESS Newswire / January 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Enfusion board breached its fiduciary duties to shareholders.
LOS ANGELES, CA / ACCESS Newswire / January 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Enfusion board breached its fiduciary duties to shareholders.
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
LOS ANGELES, CA / ACCESS Newswire / January 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Enfusion board breached its fiduciary duties to shareholders.
LOS ANGELES, CA / ACCESS Newswire / January 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Enfusion board breached its fiduciary duties to shareholders.
LOS ANGELES, CA / ACCESS Newswire / January 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Enfusion board breached its fiduciary duties to shareholders.
FAQ
- What is the ticker symbol for Enfusion?
- Does Enfusion pay dividends?
- What sector is Enfusion in?
- What industry is Enfusion in?
- What country is Enfusion based in?
- When did Enfusion go public?
- Is Enfusion in the S&P 500?
- Is Enfusion in the NASDAQ 100?
- Is Enfusion in the Dow Jones?
- When was Enfusion's last earnings report?
- When does Enfusion report earnings?
- Should I buy Enfusion stock now?